Australian shares have shown a positive shift following the successful meeting between Anthony Albanese and Donald Trump, which focused on critical minerals and the AUKUS partnership. As investors navigate these developments, attention turns to penny stocks, a term that may seem outdated but still holds significance for those seeking unique opportunities. These smaller or newer companies can offer a blend of affordability and growth potential when backed by strong financials, making them intriguing options in today's market landscape.

Top 10 Penny Stocks In Australia

Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$2.70 A$125.48M ★★★★★★ Dusk Group (ASX:DSK) A$0.90 A$56.35M ★★★★★★ IVE Group (ASX:IGL) A$2.65 A$410.95M ★★★★★☆ MotorCycle Holdings (ASX:MTO) A$3.32 A$245.04M ★★★★★★ Pureprofile (ASX:PPL) A$0.042 A$47.96M ★★★★★★ Veris (ASX:VRS) A$0.07 A$38.45M ★★★★★★ West African Resources (ASX:WAF) A$3.04 A$3.47B ★★★★★★ LaserBond (ASX:LBL) A$0.50 A$59.04M ★★★★★★ Praemium (ASX:PPS) A$0.83 A$397.09M ★★★★★★ Clover (ASX:CLV) A$0.695 A$116.9M ★★★★★★

Click here to see the full list of 422 stocks from our ASX Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Cyclopharm

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Cyclopharm Limited manufactures and sells medical equipment and radiopharmaceuticals across the Asia Pacific, Europe, Canada, the United States, and internationally, with a market cap of A$81.13 million.

Operations: The company's revenue is primarily derived from its Medical Imaging Systems segment, which generated A$30.72 million.

Market Cap: A$81.13M

Cyclopharm Limited, with a market cap of A$81.13 million, is navigating the challenges typical of penny stocks. The company remains unprofitable, with a net loss of A$7.69 million reported for H1 2025 despite revenue growth to A$15.42 million from the previous year. Cyclopharm's short-term assets significantly exceed its liabilities, and it operates debt-free, suggesting some financial stability amidst volatility. However, it has less than a year of cash runway and was recently dropped from the S&P/ASX All Ordinaries Index, highlighting potential risks in liquidity and market perception while trading below estimated fair value offers some relative attractiveness against peers.

Dive into the specifics of Cyclopharm here with our thorough balance sheet health report. Evaluate Cyclopharm's prospects by accessing our earnings growth report.ASX:CYC Financial Position Analysis as at Oct 2025

Duratec

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Duratec Limited, listed as ASX:DUR, provides assessment, protection, remediation, and refurbishment services for steel and concrete infrastructure in Australia with a market cap of A$517.46 million.

Story Continues

Operations: Duratec's revenue is generated from several segments, including Defence (A$181.36 million), Mining & Industrial (A$136.65 million), Buildings & Facades (A$111.87 million), Energy (A$82.51 million), and Other Segments (A$60.64 million).

Market Cap: A$517.46M

Duratec Limited, with a market cap of A$517.46 million, showcases a stable financial position in the penny stock landscape. The company reported revenues of A$573.03 million for FY2025, with net income rising to A$22.83 million. Duratec's diverse revenue streams across sectors like Defence and Mining provide resilience against market fluctuations. Its debt management is prudent, as cash exceeds total debt and operating cash flow comfortably covers debt obligations. Recent board changes enhance governance strength, while earnings growth forecasts suggest continued profitability improvement despite slower growth compared to its five-year average performance trajectory.

Jump into the full analysis health report here for a deeper understanding of Duratec. Learn about Duratec's future growth trajectory here.ASX:DUR Debt to Equity History and Analysis as at Oct 2025

Starpharma Holdings

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Starpharma Holdings Limited is a biopharmaceutical company focused on the research, development, and commercialization of dendrimer technology for various applications in pharmaceuticals and healthcare, with a market capitalization of A$108.74 million.

Operations: The company's revenue is derived from the discovery, development, and commercialization of dendrimers, amounting to A$5.85 million.

Market Cap: A$108.74M

Starpharma Holdings, with a market cap of A$108.74 million, operates in the biopharmaceutical sector focusing on dendrimer technology. Despite reporting sales of A$4.91 million for FY2025, the company remains pre-revenue and unprofitable, with a net loss of A$9.99 million. Recent collaborations with Radiopharm Theranostics and Genentech highlight potential future revenue streams through significant milestone payments and royalties if successful developments occur. Starpharma's financial stability is supported by cash reserves exceeding total debt and sufficient short-term assets to cover liabilities, though its share price has been highly volatile recently amidst these strategic developments.

Click here and access our complete financial health analysis report to understand the dynamics of Starpharma Holdings. Gain insights into Starpharma Holdings' future direction by reviewing our growth report.ASX:SPL Debt to Equity History and Analysis as at Oct 2025

Where To Now?

Access the full spectrum of 422  ASX Penny Stocks by clicking on this link. Searching for a Fresh Perspective? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:CYC ASX:DUR and ASX:SPL.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments